Quantitative Antibody Levels Against SARS-CoV-2 Spike Protein in COVID-19 and Multisystem Inflammatory Syndrome in Children

Basit Öğe Kaydı
dc.authorscopusid56088300100
dc.authorscopusid57414445400
dc.authorscopusid57195940496
dc.authorscopusid57222327020
dc.authorscopusid38061964200
dc.authorscopusid35611300300
dc.authorscopusid7003673004
dc.contributor.authorAvcu G.
dc.contributor.authorArslan S.Y.
dc.contributor.authorSoylu M.
dc.contributor.authorBilen N.M.
dc.contributor.authorBal Z.S.
dc.contributor.authorCicek C.
dc.contributor.authorKurugol Z.
dc.date.accessioned2023-01-12T20:23:11Z
dc.date.available2023-01-12T20:23:11Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractThe majority of children with coronavirus diseases 2019 (COVID-19) are asymptomatic or develop mild symptoms, and a small number of patients require hospitalization. Multisystem inflammatory syndrome in children (MIS-C) is one of the most severe clinical courses of COVID-19 and is suggested to be a hyperinflammatory condition. This study aimed to compare quantitative antibody levels against SARS-CoV-2 spike protein in children with COVID-19 and MIS-C. Blood samples from 75 patients [n?=?36 (48%) with mild/asymptomatic (group 1), n?=?22 (29.3%) with moderate-to-severe SARS-CoV-2 infection (group 2) and n?=?17 (22.6%) patients with MIS-C (group 3)] were analyzed 3 months after COVID-19. The majority of the children with asymptomatic/mild COVID-19 symptoms (80.6%), moderate/severe disease (90.9%), and MIS-C (82.4%) had detectable IgG antibodies to SARS-CoV-2 spike protein (p?=?0.567). The mean antibody value against SARS-CoV-2 spike protein was 321.9?±?411.6 in group 1, 274?±?261 in group 2, and 220?±?299 in group 3, respectively (p?>?0.05). Patients diagnosed with COVID-19 (asymptomatic/mild+moderate/severe) and those with MIS-C were also compared; the antibody positivity rates [COVID-19 group: 85.5%, MIS-C group: 82.4%, (p?=?0.833)] and mean antibody values [COVID-19 group: 303.9?±?360.3, MIS-C group: 220?±?299, (p?>?0.05)] were similar in both groups. In conclusion, the majority of children with COVID-19 and MIS-C developed a detectable antibody level against SARS-CoV-2 spike protein 3 months after COVID-19. Quantitative antibody levels were similar in both asymptomatic/mild disease, moderate/severe disease, and MIS-C group. Long-term studies evaluating antibody responses in children with COVID-19 and MIS-C are needed for more accurate vaccine schedules.en_US
dc.identifier.doi10.1089/vim.2022.0089
dc.identifier.endpage689en_US
dc.identifier.issn1557-8976
dc.identifier.issue10en_US
dc.identifier.pmid36534467en_US
dc.identifier.scopus2-s2.0-85144284677en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage681en_US
dc.identifier.urihttps://doi.org/10.1089/vim.2022.0089
dc.identifier.urihttps://hdl.handle.net/11454/79657
dc.identifier.volume35en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherNLM (Medline)en_US
dc.relation.ispartofViral immunologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectantibody responseen_US
dc.subjectchildrenen_US
dc.subjectCOVID-19en_US
dc.subjectMIS-Cen_US
dc.subjectmultisystem inflammatory syndromeen_US
dc.subjectspike proteinen_US
dc.subjectcoronavirus spike glycoproteinen_US
dc.subjectspike protein, SARS-CoV-2en_US
dc.subjectchilden_US
dc.subjecthumanen_US
dc.subjectChilden_US
dc.subjectCOVID-19en_US
dc.subjectHumansen_US
dc.subjectSARS-CoV-2en_US
dc.subjectSpike Glycoprotein, Coronavirusen_US
dc.titleQuantitative Antibody Levels Against SARS-CoV-2 Spike Protein in COVID-19 and Multisystem Inflammatory Syndrome in Childrenen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu